Clinical Trial Update: Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab plus apatinib versus apatinib alone as third-line treatment for metastatic gastric cancer, status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN